Liraglutide 3 mg (Saxenda)
Liraglutide 3 mg (Saxenda) is an intervention with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
Liraglutide 3 mg for Knee Osteoarthritis
Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis
Clinical Trials (6)
Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
Liraglutide 3 mg for Knee Osteoarthritis
Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis
Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance
All 6 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 6